Farmas USA

AMRN

No perder los 2$, mas aun no perder los 1,94.

La MM50 la tenemos en 2,15 ayer freno ahi pero hay que tener en cuenta la sesion global que tuvimos ...

Por los 2,30 deberian ser proximo objetivo en mi opinion ...

 

Uno todo eso que dices de CLDX a un grafico mensual de 13 años que como en Mayo supere los 33$ vais a ver fuegos artificiales de verdad ...

 

 

 

y mucha confusión con CLDN y todo lo que querais pero a la hora de parar los pies a ese "error" de la masa ... esta claro que dijeron basta donde y precisamente tenian que hacerlo para no dar señales inequivocas al mercado.

Aqui el grafico semanal

 

CLDX

MNKD Sanofi presenta resultados y da 1M en ventas para Afrezza. Creo que los analistos esperaban de 3 a 4 mill. Modo:correquetepillo

¿Creéis que la dilución de INO será mala como casi siempre o hay algo de esperanza? En los foros que leo no queda del todo claro... Yo llevo un pequeño paquete (por suerte) a 10.00. Ayer, bueno, de hecho llevo varios días, tentado de venderlas, para cambiar esos cromos por otros, por el mortal aburrimiento que me transmitían.. Lástima no haber tocado ayer las teclas... Estoy lento de reflejos desde ADXS porque todo lo que pienso se cumple para bien o para mal, pero no lo hago... Ooogggg...!!!

No acabo de "ver" el tema técnico igual que tu en este punto Framus. Al menos en lo que al segundo gráfico que pegas se refiere. 

De hecho en mi gráfico se me escapa del canal alcista y perfora la directriz claramente. Ahora tendría que vender. No lo pienso hacer.. aún....

Creo que es porque yo uso un gráfico en escala logarítmica y tu uno en líneal, y entonces no nos concuerdan las líneas. 

Pego la fotito. 

CLDX

 

 

Threshold Pharmaceuticals Reports First Quarter 2015 Financial and Operational Results
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/30/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the first quarter 2015. Revenue for the first quarter ended March 31, 2015 was $3.7 million. The operating loss for the first quarter ended March 31, 2015 was $9.6 million. The net loss for the first quarter ended March 31, 2015 was $11.2 million, which included the operating loss of $9.6 million and non-cash expense of $1.5 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of March 31, 2015, Threshold had $83.1 million in cash, cash equivalents and marketable securities, with no debt outstanding.

"Our two pivotal clinical trials with evofosfamide remain on track," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "Based on current projections, we expect that the number of protocol-specified events for the pivotal Phase 3 trials of evofosfamide in patients with advanced soft tissue sarcoma as well as in patients with advanced pancreatic cancer (MAESTRO) may be reached in the second half of 2015, with the results of the primary efficacy analyses to be available shortly thereafter. We look forward to providing clinical updates on earlier-stage programs with evofosfamide at upcoming medical meetings. In addition, we are pleased with the level of interest in our first data presentation on TH-4000, our proprietary hypoxia-activated epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), at the recent AACR annual meeting. We are looking forward to initiating two Phase 2 clinical trials of TH-4000 this year, the first in patients with EGFR-positive, T790M-negative non-small cell lung cancer and the second in patients with head and neck cancer."

First Quarter 2015 Financial and Operational Results

Revenue of $3.7 million was recognized for both the first quarter of 2015 and 2014. Revenue related to the amortization of the aggregate of $110 million in upfront and milestone payments earned in 2013 and 2012 from Threshold's collaboration with Merck KGaA, Darmstadt, Germany. The revenue from the upfront payment and milestone payments earned under the agreement is being amortized over the relevant performance period, rather than being immediately recognized when the upfront payment and milestone are earned or received.

The net loss for the first quarter of 2015 was $11.2 million compared to a net loss of $7.1 million for the first quarter of 2014. Included in the net loss for the first quarter of 2015 was an operating loss of $9.6 million and non-cash expense of $1.5 million compared to an operating loss of $8.6 million and non-cash income of $1.5 million included in the net loss for the first quarter of 2014. The non-cash income or expense is related to the change in fair value of the Company's outstanding warrants and was classified as other income (expense).

Research and development expenses were $10.7 million for the first quarter of 2015 compared to $9.7 million for the first quarter of 2014. The increase in research and development expenses was due primarily to a $0.5 million increase in clinical development expenses, net of reimbursement from Merck KGaA, Darmstadt, Germany related to their 70% share of total development expenses for evofosfamide (previously known as TH-302), and an increase of $0.5 million in consulting and employee related expenses.

General and administrative expenses were $2.6 million for both the first quarter of 2015 and 2014.

Non-cash stock-based compensation expense included in total operating expenses was $1.4 million for the first quarter of 2015 versus $1.3 million for the first quarter of 2014. The increase in stock-based compensation expense was due to the amortization of a greater number of options with higher fair values.

As of March 31, 2015 and December 31, 2014, Threshold had $83.1 million and $58.6 million in cash, cash equivalents and marketable securities, respectively. The net increase of $24.5 million in cash, cash equivalents and marketable securities during the first quarter of 2015 was primarily due to the $28.1 million in net proceeds from our public offering in February 2015, and a $7.2 million reimbursement payment related to Merck KGaA, Darmstadt, Germany's 70% share of total development expenses for evofosfamide for the fourth quarter of 2014, partially offset by the Company's operating cash requirements for the first quarter of 2015.

First Quarter and Recent Key Achievements

Corporate
In February, Threshold completed an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock. The net proceeds to Threshold from this offering were $28.1 million, which the Company expects to use for working capital and general corporate purposes, including research and development expenses, general and administrative expenses and manufacturing expenses.

Research & Development
In April, Threshold presented data on its investigational drugs at the annual meeting of the American Association for Cancer Research (AACR) 2015. Data on TH-4000, the Company's proprietary, hypoxia-activated irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), were presented in collaboration with its co-inventors from The University of Auckland (Abstract 5358). The Company believes the data presented support its two planned Phase 2 proof-of-concept clinical trials of TH-4000 in patients with mutant EGFR-positive non-small cell lung cancer (NSCLC) after conventional EGFR-TKI therapy has failed as well as in patients with head and neck cancer for which EGFR over-expression is associated with worse outcomes. In addition, preclinical data evaluating the potential use of evofosfamide in a variety of tumor types were presented by Threshold and Merck KGaA, Darmstadt, Germany (Abstract Nos. 2424, 2603, 3867, 5271, and 5333).

Clinical Development Outlook for Company- and Merck KGaA, Darmstadt, Germany-Sponsored Trials of Evofosfamide

The development plan for evofosfamide is designed to investigate its safety and efficacy across a broad range of solid tumors and hematologic malignancies. Evofosfamide is being developed in therapeutic areas supported by preclinical and clinical data and where there is high unmet need for new anti-cancer agents. To date, evofosfamide has been evaluated in more than 1,500 patients with cancer. Threshold anticipates the following development activities related to Company- and Merck KGaA, Darmstadt, Germany-sponsored clinical trials for evofosfamide in 2015:

Continue to efficiently execute the two Phase 3 clinical trials of evofosfamide to allow for timely data analyses and to prepare for the potential submission of marketing applications, assuming the data from the trials are supportive;
Continue enrollment in the Phase 2 clinical trial of evofosfamide designed to support registration for the treatment of patients with non-squamous non-small cell lung cancer;
Complete enrollment in the Phase 2 clinical trial of evofosfamide in combination with bortezomib (Velcade®) and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma; and
Continue to enroll patients in the Company's Phase 2 biomarker trial in patients with advanced melanoma.
Clinical Development Outlook for Company-Sponsored Trials of TH-4000

Threshold is planning to initiate two Phase 2 proof-of-concept clinical trials of TH-4000 in 2015; one in patients with EGFR-positive, T790M-negative non-small cell lung cancer after conventional EGFR-TKI therapy has failed, and one in patients with head and neck cancer for which EGFR over-expression is associated with worse outcomes.

About Evofosfamide

Evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, is designed to be activated under tumor hypoxic conditions, a hallmark of many cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood supply as a result of aberrant vasculature. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic.

Evofosfamide is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS), and the other in combination with gemcitabine versus gemcitabine and placebo in patients with locally advanced unresectable or metastatic pancreatic cancer (the MAESTRO trial). Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. The FDA and the European Commission have granted evofosfamide Orphan Drug Designation for the treatment of STS and pancreatic cancer. Evofosfamide is also being investigated in a Phase 2 trial designed to support registration for the treatment of non-squamous non-small cell lung cancer, and in earlier-stage clinical trials of other solid tumors and hematological malignancies.

Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S.

About TH-4000

In September 2014, Threshold licensed exclusive worldwide rights to a clinical development program based on TH-4000 (formerly referred to as PR610 or Hypoxin™) from the University of Auckland. TH-4000 is a hypoxia-activated epidermal growth factor receptor, or EGFR, tyrosine-kinase inhibitor (TKI). TH-4000 is designed to selectively release an irreversible EGFR-TKI in hypoxic tumors. Preclinical and Phase 1 clinical data suggest that plasma concentrations of TH-4000 that are active in EGFR-dependent tumor xenograft models in mice could be attained in patients with an acceptable therapeutic index.

Threshold expects to initiate Phase 2 proof-of-concept clinical trials in patients with EGFR-positive, T790M-negative non-small cell lung cancer (NSCLC) after conventional EGFR-TKI therapy has failed, and in patients with head and neck cancer.

• Threshold Pharmaceuticals (NASDAQ:THLD): Q1 EPS of -$0.17 may not be comparable to consensus of -$0.12.
• Revenue of $3.68M (flat Y/Y) beats by $0.23M.

THLD

 

No se pero THLD no me gusta: en el foro de rankia hay un blog exclusiva a ella desde hace mucho, y los valores tan puestos en boca desde hace tanto tiempo no me gustan. Puede que haga lo contrario que se espera de ella.
A NVAX espero que tenga tiempo a subir antes de estar mediáticamente nombrada.